"EC approves AstraZeneca’s Calquence combo to treat MCL" was originally created and published by Pharmaceutical Technology, a ...

AstraZeneca (AZ) has announced that its Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) has been approved ...

Calquence (acalabrutinib) plus bendamustine and rituximab reduced risk for disease progression or death by 27% compared with ...

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the European Union (EU) for the treatment of adult patients with previously untreated mantle ...

Cambridge: AstraZeneca has announced that Calquence (acalabrutinib) in combination with bendamustine and rituximab has been ...

UK pharma major AstraZeneca (LSE: AZN) today revealed that its Calquence (acalabrutinib) in combination with bendamustine and ...

AstraZeneca (LSE:AZN) recently experienced positive developments, including the European approval of Calquence for mantle ...

London open The FTSE 100 is expected to open flat on Tuesday, having closed up 1.17% before the long weekend on Friday at 8,596.35.

(Alliance News) - AstraZeneca PLC on Tuesday said Calquence plus chemoimmunotherapy has been approved in the European Union for previously untreated mantle cell lymphoma in adults. The Cambridge ...

(Sharecast News) - AstraZeneca announced on Tuesday that it has secured European Commission approval for 'Calquence', or acalabrutinib, in combination with bendamustine and rituximab for the ...